



2026 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan

中華民國血液及骨髓移植學會(TBMT)暨中華民國血液病學會(HST)聯合學術演講年會一日程總表

April 18 (Saturday)				
時間/講堂	201 會議室	301 會議室	402AB 會議室	401 會議室
08:00	中華民國血液及骨髓移植學會暨中華民國血液病學會聯合學術演講年會開幕(請會員直接至各會議室聽講)			
08:10-08:55	<b>Satellite Symposium (1)</b> <sup>挪威</sup> <b>Moderator: 陳彩雲</b> 現場	<b>Satellite Symposium (2)</b> <sup>武田</sup> <b>Moderator: 周文堅</b> 現場	<b>Satellite Symposium (3)</b> <sup>Gilead</sup> <b>Moderator: 李啟誠</b> 現場	
	Navigating Invasive Mold Diseases Management in High-Risk Patients: A Multidisciplinary Approach to Diagnosis and Treatment <i>Prof. Paul Eduard Verweij (Netherlands)</i>	Advanced Strategies in HSCT CMV Management: From Evidence to 2026 EBMT Clinical Insights <i>Dr. Cheng-Hong Tsai (Taiwan)</i>	Advancing care in r/r DLBCL <i>Prof. Miguel Perales (USA)</i>	
09:00-09:45	<b>Satellite Symposium (4)</b> <sup>AZ</sup> <b>Moderator: 黃威翰</b> 視訊	<b>Satellite Symposium (5)</b> <sup>大冨華嘉</sup> <b>Moderator: 陳宇欽</b> 現場	<b>Satellite Symposium (6)</b> <sup>GSK</sup> <b>Moderator: TBD</b> 現場	09:00-09:45
	Long-Term ravulizumab efficacy and the Strategic Use of danicopan for PNH patients. <i>Prof. Jeff Szer (Australia)</i>	From Evidence to Practice: Decision Frameworks for TPO-Receptor Agonists in Severe Aplastic Anemia <i>Dr. Hung Lin Liu (Taiwan)</i>	Comprehensive Control for Patients with Cytopenic Myelofibrosis <i>Prof. Goh Yeow Tee (Singapore)</i>	
09:50-10:35	醫師會員演講(01)	醫師會員演講(02)	醫師會員演講(03)	10:00-11:00
10:40-11:25	醫師會員演講(04)	醫師會員演講(05)	醫師會員演講(06)	
11:30-12:15	<b>Keynote Speech (1) – TBMT</b> <b>Moderator: 葉士芃</b> 現場	會員請至第 201 會議室聽講	會員請至第 201 會議室聽講	會員請至第 201 會議室聽講
	CD7 CAR-T Therapy for Treating Relapsed/Refractory T-ALL/LBL <i>Prof. Peihua Lu / Beijing Lu Daopei Hospital, China</i>			

April 18 (Saturday)				
時間/講堂	201 會議室	301 會議室	402AB 會議室	401 會議室
12:20-13:00	TBMT 會員大會 (含午餐) 頒發年會贊助廠商感謝狀	TBMT 會員 請至第 201 會議室參加會員大會	TBMT 會員 請至第 201 會議室參加會員大會	TBMT 會員 請至第 201 會議室參加會員大會
13:05-13:50	Satellite Symposium (8) <sup>GSK</sup> Moderator: 滕傑林 現場	Satellite Symposium (9) <sup>諾華</sup> Moderator: 周聖傑 視訊	Satellite Symposium (10) <sup>羅氏</sup> Moderator: 黃泰中 現場	護理
	Redefining Treatment Landscape in Relapsed/Refractory Multiple Myeloma <i>Prof. Chng Wee Joo (Singapore)</i>	Optimizing PNH Management: Striving for Hemoglobin Normalization and Clinically Meaningful Improvements with Iptacopan <i>Dr. Austin G Kulasekararaj (UK)</i>	Expanding Curative Opportunities in R/R DLBCL through Bispecific Combination Therapy <i>Dr. Jeremy Abramson (USA)</i>	
13:55-14:40	Keynote Speech (2) – TBMT Moderator: 葉士芃 現場	會員請至第 201 會議室聽講	會員請至第 201 會議室聽講	會員請至第 201 會議室聽講
	Future Perspectives of DLBCL and Strategies for High-Risk Populations <i>Dr. Jeremy Abramson (USA)</i>			
14:40-14:50	Break			護理
14:50-17:55	HST-EHA Joint Symposium and Special Lecture	醫師會員請至 201 會議室聽講	醫師會員請至 201 會議室聽講	
18:00-18:45	臺大醫院國際會議中心 201 會議室	18:30-19:15	台北喜來登飯店 2F 請客樓	
	Dinner Symposium (1) <sup>安進</sup> Moderator: 盧孟佑 現場		Dinner Symposium (2) <sup>東洋</sup> Moderator: 譚傳德 現場	
	How Can We Cure Acute Lymphoblastic Leukemia Today? <i>Dr. Daniel J. DeAngelo (USA)</i>		The Chemo-Free Pathway in Real World R/R DLBCL <i>Dr. Chieh-Lin Teng (Taiwan)</i>	
19:15	第一日會議結束			

April 19 (Sunday)				
時間/講堂	201 會議室	301 會議室	402AB 會議室	401 會議室
08:00-08:45	<b>Satellite Symposium (11)<sup>CSL</sup></b> <b>Moderator: 劉益昌</b> 現場	<b>Satellite Symposium (12)<sup>藥華醫藥</sup></b> <b>Moderator: 陳志丞</b> 現場	<b>Satellite Symposium (13)<sup>科悉</sup></b> <b>Moderator: 張鴻</b> 視訊	<b>Satellite Symposium (14)<sup>默麟</sup></b> <b>Moderator: 姚明</b> 現場
	Optimizing immunoglobulin replacement therapy in Hematologic Malignancy-Related Secondary Immunodeficiency: From Consensus to Clinical Practice <i>Prof. Hsin-An Hou (Taiwan)</i>	Modern management of Polycythemia Vera– Ropeginterferon alfa-2b demonstrates long-term disease improvements <i>Prof. Kazuya Shimoda (Japan)</i>	Redefining Complement Inhibition in PNH: The Clinical Impact of Targeting C3 <i>Prof. Jeff Szer (Australia)</i>	Mogamulizumab : A novel therapy for the treatment of Cutaneous T-cell Lymphoma <i>Prof. Eiji Kiyohara (Japan)</i>
08:50-09:35	<b>Keynote Speech (3) – HST</b> <b>Moderator: 柯博升</b>	全體學員請至第 201 會議室聽講	全體學員請至第 201 會議室聽講	全體學員請至第 201 會議室聽講
	Adoptive cancer immunotherapy with engineered T-cells <i>Prof. Chiara Bonini (Italy)</i>			
09:35-09:45	Break, Exhibition, and Poster Viewing	Break, Exhibition, and Poster Viewing	Break, Exhibition, and Poster Viewing	Break, Exhibition, and Poster Viewing
09:45-11:35	Taiwan and Japan Hematology Forum	全體學員請至第 201 會議室聽講	全體學員請至第 201 會議室聽講	全體學員請至第 201 會議室聽講
11:45-12:20	HST 青年研究發展獎口頭研究計畫內容報告及各項學術獎頒獎	HST 會員請至第 201 會議室參加會員大會	HST 會員請至第 201 會議室參加會員大會	HST 會員請至第 201 會議室參加會員大會
12:20-13:10	HST 會員大會暨理監事選舉(含午餐)	HST 會員請至第 201 會議室聽講及觀禮	HST 會員請至第 201 會議室聽講及觀禮	HST 會員請至第 201 會議室聽講及觀禮
13:15-14:00	<b>Satellite Symposium (15)<sup>輝瑞</sup></b> <b>Moderator: 黃聖懿</b> 現場	<b>Satellite Symposium (16)<sup>諾生</sup></b> <b>Moderator: 郭明宗</b> 視訊	<b>Satellite Symposium (17)<sup>安斯泰來</sup></b> <b>Moderator: 侯信安</b> 現場	<b>Satellite Symposium (18)<sup>武田</sup></b> <b>Moderator: 王銘崇</b> 現場
	The Long Game in Myeloma: Optimizing and Maintaining Deep Responses with BCMA BsAbs <i>Dr. Andrew Jenho Yee (USA)</i>	Optimizing the Treatment Continuum in Multiple Myeloma: From Frontline to Relapsed Disease <i>Dr. Paula Rodríguez-Otero (Spain)</i>	Optimizing Post-HSCT Maintenance Strategies for R/R FLT3m AML Management <i>Dr. Ashish Bajel (Australia)</i>	The Evolution of PET-Adapted Strategies in 1L treatment of Advanced Hodgkin Lymphoma <i>Dr. Hung Lin Liu (Taiwan)</i>
14:05-14:50	醫師會員演講(07)	醫師會員演講(08)	醫師會員演講(09)	HST 臨床試驗工作組報告 No.01-04
14:55-15:40	醫師會員演講(10)	醫師會員演講(11)	醫師會員演講(12)	HST 臨床試驗工作組報告 No.05-08

April 19 (Sunday)				
時間/講堂	201 會議室	301 會議室	402AB 會議室	401 會議室
15:40	中華民國血液及骨髓移植學會暨中華民國血液病學會聯合學術演講年會閉幕			

**PEI HUA (PEGGY) LU MD.**

E-mail: [peihua\\_lu@126.com](mailto:peihua_lu@126.com)

**Medical Director since 2015 in LU DAOPEI Medical Group in China** (Beijing Lu Daopei Hospital, Beijing Lu Daopei Hematology Hospital, Hebei Yanda Lu Daopei Hospital, Shanghai Daopei Hospital).

After graduating from Beijing University Medical School, she went to the US and obtained a license to practice medicine there. After completing her residency in the University of Nebraska Medical Center in U.S., she was admitted as a clinical fellow to the Hematology and Oncology program at Stanford University Medical Center, subsequently obtained board certification in hematology and oncology in US. She received two awards/grants from the National Institutes of Health (NIH), including a Postdoctoral Fellowship Award and a Physician Scientist Award (K11). She conducted research on Cytokine-Induced Killer (CIK) Cells under Prof. Robert Negrin at Stanford, which demonstrated significant anti-tumor activity in animal experiments. This therapy was later introduced to China for clinical application, becoming one of the earliest cellular immunotherapies developed in China. She was invited by the American Medical Association to present her personal journey of success in the U.S. at its annual meeting. She holds board certifications in hematology and oncology in the U.S., as well as a medical license in China. In 2015, she returned to China, where she has led multiple trials/projects and research. She has extensive research experience and clinical expertise in cellular immunotherapies such as CAR-T therapy, as well as in the fields of lymphoma, myeloma, and leukemia. She received multiple awards in China including “Taishan(泰山)” Healthcare Management Award and People's Outstanding Doctor(人民好医生) .

Professor Peihua Lu has published many high-impact papers in **Lancet Hematology, Blood** (4 papers), **Signal Transduction and Targeted Therapy, American Journal of Hematology** (3 papers), **Blood Cancer Cell, Blood Advances, Clinical Cancer Research, Molecular Therapy**, and had multiple oral presentations at ASH, EHA and EBMT focusing on CD7/CD19/BCMA-targeted CAR-T therapies for relapsed/refractory hematological malignancies.